DISCOUNT ZERTIFIKAT - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 04:20:30 2024-05-29 EDT | ||
| 130.3 EUR | +0.19% |
|
| Current month | +0.29% | ||
| 1 month | +0.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 130.3 | +0.19% |
| 24-05-28 | 130 | -1.34% |
| 24-05-24 | 131.8 | -0.36% |
| 24-05-23 | 132.2 | +0.24% |
| 24-05-22 | 131.9 | -0.18% |
Real-time Boerse Frankfurt Warrants
Last update May 29, 2024 at 04:20 am
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VZE |
| ISIN | DE000PC3VZE7 |
| Date issued | 2024-01-25 |
| Maturity | 2025-06-20 (388 Days) |
| Parity | 1 : 1 |
| Emission price | 114.7 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 132.4 € |
|---|---|
| Lowest since issue | 106.3 € |
| Spread | 0.05 € |
| Spread % | 0.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- Certificat
